Michael Gibney
Senior Editor & Writer | LinkedInMichael Gibney is a senior writer and editor for PharmaVoice. Before that, he covered the pharmaceutical industry as a healthcare reporter for three and a half years at S&P Global Market Intelligence and served as an editor at FiercePharma and FierceBiotech. Besides industry reporting, Michael has also covered science, wildlife and environmental issues as well as local news in Connecticut and Montana. A graduate of Bucknell University and the University of Missouri Journalism School, he is based in the Washington, D.C., area where you’ll find him hiking with two retired racing greyhounds, finding local breweries and grilling in the backyard.
227 articles by Michael Gibney
-
By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years
Jan. 16, 2025 -
Will 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A?
Jan. 14, 2025 -
After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win
Jan. 9, 2025 -
How pharma was instrumental in President Jimmy Carter’s global health efforts
Jan. 3, 2025 -
Merck’s RSV antibody could soon paddle into the rough waters of a crowded market
Dec. 19, 2024 -
Maternal mortality trends remain dire — and researchers face an uphill battle to solve them
Dec. 17, 2024 -
Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma
Dec. 12, 2024 -
GSK’s multiple myeloma ADC Blenrep was pulled from the market. Now, it’s poised for a comeback.
Dec. 10, 2024 -
How Astellas juggles the moving parts of cancer precision medicine development
Dec. 5, 2024 -
How Alexion markets a rare disease drug by ‘starting with the end in mind’
Dec. 3, 2024 -
An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond
Nov. 26, 2024 -
Keytruda represents almost half of Merck’s sales, and a new formulation could fend off rivals
Nov. 21, 2024 -
What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine
Nov. 19, 2024 -
Left to clean up after ‘pharma bro’ Shkreli’s arrest, former Turing CEO Ron Tilles reckons with the past
Nov. 14, 2024 -
Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in
Nov. 7, 2024 -
Two former Alexion leaders fight through a tough market to maintain a rare disease biotech
Nov. 5, 2024 -
2024 PharmaVoice 100s: Cancer Care Visionaries
Nov. 1, 2024 -
Big Pharma earnings hang hope on the next generation of blockbusters
Oct. 31, 2024 -
2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers
Oct. 30, 2024 -
How AZ’s respiratory wins are ramping up for a bigger prize in COPD
Oct. 29, 2024 -
2024 PharmaVoice 100s: Biotech Pathfinders
Oct. 23, 2024 -
With activist investment rising, Pfizer’s battle with Starboard reflects the industry’s post-pandemic tumble
Oct. 22, 2024 -
As new Alzheimer’s biomarkers come into play, here’s where the money is going
Oct. 17, 2024 -
AlphaFold’s Nobel Prize is ‘the dawn of a new era’ in mapping drug development potential
Oct. 15, 2024 -
Regeneron takes the long-haul approach to oncology, stumbles and all
Oct. 10, 2024